EA201170160A1 - Новые ингибиторы пролиферации и активации переносчика сигнала и активатора транскрипции (stats) - Google Patents
Новые ингибиторы пролиферации и активации переносчика сигнала и активатора транскрипции (stats)Info
- Publication number
- EA201170160A1 EA201170160A1 EA201170160A EA201170160A EA201170160A1 EA 201170160 A1 EA201170160 A1 EA 201170160A1 EA 201170160 A EA201170160 A EA 201170160A EA 201170160 A EA201170160 A EA 201170160A EA 201170160 A1 EA201170160 A1 EA 201170160A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- activation
- stats
- proliferation
- signal transfer
- new inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/57—Nitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Предлагаются пиридиновые соединения, эффективные в модуляции активации STAT3 и/или STAT5, эти соединения пригодны к применению для профилактики и лечения пролиферативных заболеваний и состояний, включая рак, воспаление и пролиферативные болезни кожи.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7900208P | 2008-07-08 | 2008-07-08 | |
PCT/US2009/048782 WO2010005807A2 (en) | 2008-07-08 | 2009-06-26 | Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (stats) |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201170160A1 true EA201170160A1 (ru) | 2011-08-30 |
EA020766B1 EA020766B1 (ru) | 2015-01-30 |
Family
ID=41507673
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201170160A EA020766B1 (ru) | 2008-07-08 | 2009-06-26 | Ингибиторы пролиферации и активации переносчика сигнала и активатора транскрипции (stats) |
Country Status (18)
Country | Link |
---|---|
US (3) | US8143412B2 (ru) |
EP (1) | EP2307367B1 (ru) |
JP (1) | JP5675606B2 (ru) |
KR (1) | KR20110033922A (ru) |
CN (1) | CN102143947B (ru) |
AU (1) | AU2009268841B2 (ru) |
BR (1) | BRPI0915697A2 (ru) |
CA (1) | CA2729943A1 (ru) |
CR (1) | CR20110074A (ru) |
EA (1) | EA020766B1 (ru) |
ES (1) | ES2521676T3 (ru) |
IL (1) | IL210423A0 (ru) |
MX (1) | MX2011000268A (ru) |
NZ (1) | NZ590372A (ru) |
PL (1) | PL2307367T3 (ru) |
UA (1) | UA103492C2 (ru) |
WO (1) | WO2010005807A2 (ru) |
ZA (1) | ZA201100536B (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2689548C2 (ru) * | 2012-10-31 | 2019-05-28 | Ионис Фармасьютикалз, Инк. | Лечение рака |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090082507A (ko) | 2006-11-20 | 2009-07-30 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 통증 및 소양증 치료용 방법, 조성물 및 키트 |
UA103492C2 (ru) | 2008-07-08 | 2013-10-25 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Ингибиторы пролиферации и активации переносчика сигнала и активатора транскрипции (stats) |
CA3027255C (en) | 2009-07-10 | 2022-06-21 | The General Hospital Corporation | Permanently charged sodium and calcium channel blockers as anti-inflammatory agents |
WO2011069141A2 (en) | 2009-12-04 | 2011-06-09 | Board Of Regents, The University Of Texas System | Interferon therapies in combination with blockade of stat3 activation |
US20110275577A1 (en) * | 2010-01-08 | 2011-11-10 | Moleculin, Llc | Methods of treating dermatologic, gynecologic, and genital disorders with caffeic acid analogs |
US10130632B2 (en) | 2012-11-27 | 2018-11-20 | Beth Israel Deaconess Medical Center, Inc. | Methods for treating renal disease |
CA2962757C (en) * | 2014-09-26 | 2022-03-22 | National University Of Singapore | Methods and compositions for modulating th-gm cell function |
JP6833811B2 (ja) | 2015-08-03 | 2021-02-24 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 荷電イオンチャネル遮断薬及び使用方法 |
EP3461916A1 (en) * | 2017-10-02 | 2019-04-03 | Koninklijke Philips N.V. | Assessment of jak-stat3 cellular signaling pathway activity using mathematical modelling of target gene expression |
TWI846678B (zh) * | 2017-11-10 | 2024-07-01 | 美國德州系統大學評議委員會 | 咖啡酸衍生物及其用途 |
US10780083B1 (en) | 2019-03-11 | 2020-09-22 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
US10786485B1 (en) | 2019-03-11 | 2020-09-29 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
MA55320A (fr) | 2019-03-11 | 2022-01-19 | Nocion Therapeutics Inc | Bloqueurs de canaux ioniques substitués par un ester et méthodes d'utilisation |
US10968179B2 (en) | 2019-03-11 | 2021-04-06 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
EP3937945A4 (en) | 2019-03-11 | 2023-01-04 | Nocion Therapeutics, Inc. | CHARGED ION CHANNEL BLOCKERS AND METHODS OF USE |
US11485750B1 (en) | 2019-04-05 | 2022-11-01 | Kymera Therapeutics, Inc. | STAT degraders and uses thereof |
WO2021091585A1 (en) | 2019-11-06 | 2021-05-14 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
US10933055B1 (en) | 2019-11-06 | 2021-03-02 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
AU2021236130A1 (en) | 2020-03-11 | 2022-09-22 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL277744A (ru) | 1961-05-19 | |||
DE2555789A1 (de) | 1975-12-11 | 1977-07-07 | Hoechst Ag | Neue cyanessigsaeureanilid-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel |
US6610830B1 (en) | 1980-07-01 | 2003-08-26 | Hoffman-La Roche Inc. | Microbial production of mature human leukocyte interferons |
US4414150A (en) | 1980-11-10 | 1983-11-08 | Genentech, Inc. | Hybrid human leukocyte interferons |
US4456748A (en) | 1981-02-23 | 1984-06-26 | Genentech, Inc. | Hybrid human leukocyte interferons |
US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
DE3410439A1 (de) | 1984-03-22 | 1985-09-26 | Hoechst Ag, 6230 Frankfurt | Verfahren zur herstellung von 6-methyl-3,4-dihydro-1,2,3-oxathiazin-4-on-2,2-dioxid und dessen nichttoxischen salzen sowie der dabei als zwischenprodukt(e) auftretenden acetoacetamind-n-sulfonsaeure(salze) |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4917888A (en) | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
FR2629455B1 (fr) | 1988-03-29 | 1991-09-27 | Rhone Poulenc Agrochimie | Derives de 2-(3-pyridinyl)3-(phenoxy) propanenitrile |
GB9004483D0 (en) | 1990-02-28 | 1990-04-25 | Erba Carlo Spa | New aryl-and heteroarylethenylene derivatives and process for their preparation |
US5196446A (en) | 1990-04-16 | 1993-03-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Certain indole compounds which inhibit EGF receptor tyrosine kinase |
JPH05507072A (ja) | 1990-04-16 | 1993-10-14 | イッスム リサーチ ディヴェロプメント カンパニー オブ ザ ヒーブルー ユニヴァーシティ オブ エルサレム | Egfレセプタチロシンキナーゼを阻害する複素環式エテンジイル化合物 |
JPH05301838A (ja) | 1991-10-15 | 1993-11-16 | Mitsubishi Kasei Corp | スチレン誘導体 |
CA2080554A1 (en) | 1991-10-15 | 1993-04-16 | Mitsubishi Chemical Corporation | Styrene derivatives |
CA2092017A1 (en) | 1992-03-26 | 1993-09-27 | Tameo Iwasaki | Butadiene derivatives and process for preparing the same |
US5981569A (en) | 1992-11-13 | 1999-11-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease |
JPH06247850A (ja) | 1993-02-24 | 1994-09-06 | Suntory Ltd | 12−リポキシゲナーゼ阻害剤 |
DE4330105A1 (de) | 1993-09-06 | 1995-03-09 | Bayer Ag | Verwendung von beta-Hetaryl-beta-oxopropionsäurenitrile als Schädlingsbekämpfungsmittel |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
GB9322781D0 (en) | 1993-11-04 | 1993-12-22 | Roussel Lab Ltd | Aromatic amides |
US5951974A (en) | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
NZ276943A (en) | 1993-11-10 | 1998-02-26 | Schering Corp Substituted For | Alpha-interferon conjugated to a non-antigenic polymer (preferably a polyalkylene oxide) and its preparation |
IL107736A (en) | 1993-11-24 | 2001-01-11 | Yissum Res Dev Co | Pharmaceutical composition for the prevention of septic shock and for the treatment of chronic inflammatory diseases |
IL112205A0 (en) | 1994-01-06 | 1995-03-15 | Res Dev Foundation | Curcumin, analogues of curcumin and novel uses thereof |
US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
AU2096895A (en) | 1994-03-07 | 1995-09-25 | Sugen, Incorporated | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
GB9406137D0 (en) | 1994-03-28 | 1994-05-18 | Erba Carlo Spa | N-substituted beta-aryl- and betaheteroaryl-alpha-cyanoacrylamide derivatives and process for their preparation |
WO1995028922A1 (en) | 1994-04-22 | 1995-11-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of benzylidene-malononitrile derivates for the treatment of leukemia |
US5738846A (en) | 1994-11-10 | 1998-04-14 | Enzon, Inc. | Interferon polymer conjugates and process for preparing the same |
US6331555B1 (en) | 1995-06-01 | 2001-12-18 | University Of California | Treatment of platelet derived growth factor related disorders such as cancers |
TW517067B (en) | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
IL119069A0 (en) | 1996-08-14 | 1996-11-14 | Mor Research Applic Ltd | Pharmaceutical composition comprising tyrphostins |
US20020119129A1 (en) | 1997-01-15 | 2002-08-29 | Yeda Research And Development Co. Ltd. | Novel IFN receptor 1 binding proteins, DNA encoding them, and methods of modulating cellular response to interferons |
DE19707319C1 (de) | 1997-02-12 | 1998-06-18 | Mannesmann Ag | Verfahren und Einrichtung zum Positionieren der Mündung einer verzehrbaren Lanze |
US5854285A (en) | 1997-04-03 | 1998-12-29 | Natpro, Inc. | Protein kinase inhibitor |
US6420338B1 (en) | 1997-06-13 | 2002-07-16 | New York University Medical Center | Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma |
AU737018B2 (en) | 1997-07-25 | 2001-08-09 | Tsumura & Co. | Pyridylacrylamide derivatives and nephritis remedies and TGF-beta inhibitors containing the same |
US6225346B1 (en) | 1997-10-24 | 2001-05-01 | Sugen, Inc. | Tyrphostin like compounds |
KR100674760B1 (ko) | 1999-03-04 | 2007-01-25 | 리가가쿠 겐큐쇼 | 촉매 조성물 |
US20020045191A1 (en) | 2000-09-15 | 2002-04-18 | Schneider Robert J. | Inhibition of the SRC kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma |
AU2002307217A1 (en) | 2001-03-28 | 2002-10-15 | University Of South Florida | Materials and methods for treatment of cancer and identification of anti-cancer compounds |
JP2003119169A (ja) | 2001-07-30 | 2003-04-23 | Shigetoshi Kadota | 細胞毒性活性を有する化合物およびそれを有効成分とする医薬組成物 |
US6433018B1 (en) | 2001-08-31 | 2002-08-13 | The Research Foundation Of State University Of New York | Method for reducing hypertrophy and ischemia |
CA2468704C (en) | 2001-11-30 | 2011-06-14 | Santen Pharmaceutical Co., Ltd. | Urea derivatives as angiogenesis inhibitors |
AU2003210983A1 (en) | 2002-02-11 | 2003-09-04 | The Brigham And Women's Hospital, Inc. | Kinase inhibitors and methods of use thereof |
US20040180889A1 (en) | 2002-03-01 | 2004-09-16 | Pintex Pharmaceuticals, Inc. | Pin1-modulating compounds and methods of use thereof |
CA2481178A1 (en) | 2002-04-02 | 2003-10-23 | Tatsuhiro Obata | Phosphodiesterase iv inhibitor containing pyridylacrylamide derivative |
WO2004047743A2 (en) | 2002-11-22 | 2004-06-10 | Bristol-Myers Squibb Company | 1-aryl-2-hydroxyethyl amides as potassium channel openers |
CH696238A5 (de) * | 2003-06-30 | 2007-02-28 | Lymphosign Inc | Verfahren zur Herstellung von Zimtaldehydverbindungen. |
KR20050055479A (ko) | 2003-12-08 | 2005-06-13 | 김철호 | 카페인산 또는 카페인산 페네틸에스테르를 유효성분으로하는 mmp-9 억제제 |
AU2004298511B2 (en) | 2003-12-11 | 2011-08-11 | Board Of Regents, The University Of Texas System | Compounds for treatment of cell proliferative diseases |
EP1727822A4 (en) * | 2004-03-26 | 2007-05-09 | Hsc Res Dev Lp | NEW COMPOUNDS FOR MODULATING CELL PROLIFERATION |
EP1748772A2 (en) | 2004-04-09 | 2007-02-07 | University Of South Florida | Combination therapies for cancer and proliferative angiopathies |
ES2245887B1 (es) | 2004-07-02 | 2007-04-01 | Marcos Serrano Gil | Rueda de timon plegable para embarcaciones. |
US7807719B2 (en) * | 2004-09-14 | 2010-10-05 | Chaim Roifman | Compounds useful for modulating abnormal cell proliferation |
JP5264177B2 (ja) | 2004-11-22 | 2013-08-14 | アボット・メディカル・オプティクス・インコーポレイテッド | 共重合性メチンおよびアントラキノン化合物およびそれらを含有する物品 |
CA2596755C (en) | 2005-02-09 | 2014-09-09 | Paul Q. Anziano | Compositions and methods for inhibiting an isoform of human manganese superoxide dismutase |
WO2007006143A1 (en) * | 2005-07-13 | 2007-01-18 | The Hospital For Sick Children | Compositions and methods for detecting transformed cells |
EP1986656A4 (en) | 2006-02-02 | 2012-05-16 | Univ South Florida | WITHACNISTINE COMPOUNDS FOR THE TREATMENT OF CANCER |
US8779151B2 (en) | 2006-03-31 | 2014-07-15 | The Board Of Regents Of The University Of Texas System | Orally bioavailable caffeic acid related anticancer drugs |
CA2651317A1 (en) | 2006-05-05 | 2007-11-15 | George Mason Intellectual Properties, Inc. | Compositions and methods for detecting and treating hiv infection |
FR2903050B1 (fr) | 2006-06-30 | 2009-02-27 | Valeo Systemes Thermiques | Dispositif d'eclairage ou de signalisation pour face avant de vehicule automobile et face avant comportant un tel dispositif |
WO2008005954A2 (en) | 2006-06-30 | 2008-01-10 | The Board Of Regents Of The University Of Texas System | Tryphostin-analogs for the treatment of cell proliferative diseases |
EP2471529A3 (en) | 2006-09-05 | 2012-10-10 | Emory University | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof |
WO2008083389A1 (en) | 2006-12-29 | 2008-07-10 | Moleculin, L.L.C. | Methods of treating skin disorders with caffeic acid analogs |
WO2008118445A1 (en) | 2007-03-26 | 2008-10-02 | Promega Corporation | Methods to quench light from optical reactions |
WO2008121858A1 (en) | 2007-03-28 | 2008-10-09 | Board Of Regents, The University Of Texas System | Small molecule inhibitors for immune modulation |
WO2009009150A2 (en) | 2007-07-12 | 2009-01-15 | Renee Michelle Cleary | Telecommunication and electronic devices holding apparatus and methods |
ES2569215T3 (es) | 2007-09-10 | 2016-05-09 | Boston Biomedical, Inc. | Un nuevo grupo de inhibidores de la ruta de Stat3 e inhibidores de la ruta de las células madre del cáncer |
US20100310563A1 (en) | 2007-11-30 | 2010-12-09 | Bumm Thomas G P | Methods for treating induced cellular proliferative disorders |
WO2009086303A2 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
US7989572B2 (en) | 2008-01-17 | 2011-08-02 | Eastman Chemical Company | Polyvinyl ultraviolet light absorbers for personal care |
UA103492C2 (ru) | 2008-07-08 | 2013-10-25 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Ингибиторы пролиферации и активации переносчика сигнала и активатора транскрипции (stats) |
US8450337B2 (en) | 2008-09-30 | 2013-05-28 | Moleculin, Llc | Methods of treating skin disorders with caffeic acid analogs |
US20120021941A1 (en) | 2009-01-12 | 2012-01-26 | The Board Of Regents Of The University Of Texas System | Blood test for the detection of cancer |
-
2009
- 2009-06-26 UA UAA201101400A patent/UA103492C2/ru unknown
- 2009-06-26 NZ NZ590372A patent/NZ590372A/xx unknown
- 2009-06-26 CA CA2729943A patent/CA2729943A1/en not_active Abandoned
- 2009-06-26 EP EP09794969.7A patent/EP2307367B1/en active Active
- 2009-06-26 CN CN200980135799.2A patent/CN102143947B/zh active Active
- 2009-06-26 WO PCT/US2009/048782 patent/WO2010005807A2/en active Application Filing
- 2009-06-26 JP JP2011517468A patent/JP5675606B2/ja active Active
- 2009-06-26 BR BRPI0915697A patent/BRPI0915697A2/pt not_active IP Right Cessation
- 2009-06-26 MX MX2011000268A patent/MX2011000268A/es active IP Right Grant
- 2009-06-26 US US12/989,944 patent/US8143412B2/en active Active
- 2009-06-26 EA EA201170160A patent/EA020766B1/ru not_active IP Right Cessation
- 2009-06-26 PL PL09794969T patent/PL2307367T3/pl unknown
- 2009-06-26 AU AU2009268841A patent/AU2009268841B2/en not_active Ceased
- 2009-06-26 KR KR1020117001487A patent/KR20110033922A/ko not_active Application Discontinuation
- 2009-06-26 ES ES09794969.7T patent/ES2521676T3/es active Active
-
2011
- 2011-01-02 IL IL210423A patent/IL210423A0/en unknown
- 2011-01-20 ZA ZA2011/00536A patent/ZA201100536B/en unknown
- 2011-02-08 CR CR20110074A patent/CR20110074A/es unknown
-
2012
- 2012-02-21 US US13/401,161 patent/US8637675B2/en active Active
-
2013
- 2013-12-11 US US14/103,619 patent/US9000179B2/en active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2689548C2 (ru) * | 2012-10-31 | 2019-05-28 | Ионис Фармасьютикалз, Инк. | Лечение рака |
Also Published As
Publication number | Publication date |
---|---|
US20110053992A1 (en) | 2011-03-03 |
PL2307367T3 (pl) | 2015-03-31 |
ES2521676T3 (es) | 2014-11-13 |
ZA201100536B (en) | 2012-06-27 |
KR20110033922A (ko) | 2011-04-01 |
WO2010005807A3 (en) | 2010-03-25 |
NZ590372A (en) | 2012-09-28 |
WO2010005807A2 (en) | 2010-01-14 |
EA020766B1 (ru) | 2015-01-30 |
MX2011000268A (es) | 2011-04-27 |
CN102143947A (zh) | 2011-08-03 |
UA103492C2 (ru) | 2013-10-25 |
US8637675B2 (en) | 2014-01-28 |
JP5675606B2 (ja) | 2015-02-25 |
US20140228414A1 (en) | 2014-08-14 |
AU2009268841B2 (en) | 2014-02-06 |
AU2009268841A8 (en) | 2011-02-03 |
CR20110074A (es) | 2011-06-24 |
CN102143947B (zh) | 2015-06-24 |
US8143412B2 (en) | 2012-03-27 |
EP2307367B1 (en) | 2014-09-24 |
US9000179B2 (en) | 2015-04-07 |
CA2729943A1 (en) | 2010-01-14 |
BRPI0915697A2 (pt) | 2016-02-10 |
IL210423A0 (en) | 2011-03-31 |
AU2009268841A1 (en) | 2010-01-14 |
JP2011527679A (ja) | 2011-11-04 |
EP2307367A2 (en) | 2011-04-13 |
US20120149738A1 (en) | 2012-06-14 |
EP2307367A4 (en) | 2012-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201170160A1 (ru) | Новые ингибиторы пролиферации и активации переносчика сигнала и активатора транскрипции (stats) | |
EA201792185A3 (ru) | Модуляция экспрессии трансдуктора сигнала и активатора транскрипции 3 (stat3) | |
CY1121450T1 (el) | Θεραπεια συνδυασμου για θεραπεια καρκινου | |
EA201300171A1 (ru) | Способы и композиции для терапии рака печени | |
EA201270100A1 (ru) | Пиримидиноны в качестве ингибиторов pi3k | |
DK1846424T3 (da) | Proteasom-inhibitorer og fremgangsmåder til anvendelse deraf | |
GEP20146060B (en) | Pyridyl inhibitors of hedgehog signalling | |
EA201170531A1 (ru) | Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака | |
CL2015002194A1 (es) | Inhbidores de erk y sus usos | |
GEP20156229B (en) | 5-alkynyl-pyrimidines | |
DK1660507T3 (da) | Proteasominibitorer og metoder til anvendelse heraf | |
EA200900819A1 (ru) | Хиназолины для ингибирования pdk1 | |
EA201170252A1 (ru) | Амидофеноксиндазолы в качестве ингибиторов c-мет | |
EA201490922A1 (ru) | ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ | |
NO20091661L (no) | Anvendelse av pegylert IL-10 for a behandle kreft | |
BR112013005116A2 (pt) | moduladores e métodos de uso | |
MY165620A (en) | Cyclopropylamines as lsd1 inhibitors | |
EA201291031A1 (ru) | Способ лечения ожирения с применением антиоксидантных модуляторов воспаления | |
CL2008001633A1 (es) | Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer. | |
EA201592108A1 (ru) | Гетероциклические соединения в качестве ингибиторов сигнального пути hedgehog | |
CL2008002185A1 (es) | Compuestos derivados de pirimidina, inhibidores de fosfatidilinositol-3-cinasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades resapiratorias, alergias, inflamacion, cancer, entre otras enfermedades. | |
DOP2012000260A (es) | Uso de nuevos inhibidores de pancdk para tratar tumores | |
EA201690376A1 (ru) | Ингибиторы дезоксицитидинкиназы | |
TN2009000448A1 (en) | Use of hdac inhibitors for the treatment of bone destruction | |
CL2012000461A1 (es) | Compuestos derivados de piridina fusionada con otro heterociclo, inhibidores del smo; composicion farmaceutica; y uso para la profilaxis o tratamiento del cancer. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KZ KG MD TJ TM |